EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

EpiVax, Inc. India Rhode Island

to the FDA, supporting regulatory filing of Abbreviated New Drug Applications (ANDA) of generic peptide drugs. EpiVax's PANDA® MMF provides detailed descriptions of its models and methodologies for assessing the immunogenicity of peptide drugs and their impurities and can now be referenced as a Drug Master File (DMF) in FDA ANDA fillings. The accessibility of EpiVax's PANDA® MMF represents an important step in streamlining the preparation and review of ANDAs, enabling sponsors to simplify their regulatory package and FDA reviewers to access in-depth background and validation information regarding  EpiVax's immunogenicity models.

EpiVax remains committed to driving innovation with several planned improvements for the ISPRI platform upcoming, including a new version of EpiMatrix® to further enhance the toolkit's predictive capabilities. Additionally, guided analysis features and an updated user interface for ISPRI will provide a more user-friendly experience, empowering our partners in strengthening their pipelines.

About EpiVax
EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for peptide therapeutics, biologic therapeutics, and vaccines. EpiVax partners with a global roster of companies, agencies, and academics to accelerate immunogenicity risk assessment, immune modulation, and rapid vaccine design.

Press Contact
Sarah Moniz
Director, Business Development
EpiVax
[e-mail]

Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/epivax-strengthens-technology-leadership-amid-immunoinformatics-advancements-302387204.html